These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11459212)

  • 1. Renal implications of angiotensin receptor blockers.
    Hollenberg NK
    Am J Hypertens; 2001 Jul; 14(7 Pt 2):237S-241S. PubMed ID: 11459212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy.
    Narita I; Goto S; Saito N; Song J; Omori K; Kondo D; Sakatsume M; Gejyo F
    Kidney Int; 2003 Sep; 64(3):1050-8. PubMed ID: 12911556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE insertion/deletion polymorphism and diabetic nephropathy: clinical implications of genetic information.
    Ha SK
    J Diabetes Res; 2014; 2014():846068. PubMed ID: 25587546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL; Gleason BL
    Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors?
    Giles TD; Sander GE
    Am J Geriatr Cardiol; 2002; 11(1):62-5. PubMed ID: 11773721
    [No Abstract]   [Full Text] [Related]  

  • 15. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.
    Ruggenenti P; Bettinaglio P; Pinares F; Remuzzi G
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1511-25. PubMed ID: 18550651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Diabetic Nephropathy: Core Curriculum 2018.
    Umanath K; Lewis JB
    Am J Kidney Dis; 2018 Jun; 71(6):884-895. PubMed ID: 29398179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.